Related Experiment Video
Updated: Aug 10, 2025
14:26
Purification of Extracellular Trypanosomes, Including African, from Blood by Anion-Exchangers Diethylaminoethyl-cellulose Columns
Published on: April 6, 2019
10.3K
Drugging the Undruggable Trypanosoma brucei Monothiol Glutaredoxin 1
Annagiulia Favaro1, Giovanni Bolcato1, Marcelo A Comini2
1Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131 Padova, Italy.
Molecules (Basel, Switzerland)
|February 11, 2023
Summary
Researchers identified a small molecule targeting the unique redox system of Trypanosoma brucei, the parasite causing sleeping sickness. This discovery offers a novel therapeutic strategy against this challenging parasitic infection.
Area of Science:
- Parasitology
- Biochemistry
- Drug Discovery
Background:
- Trypanosoma brucei causes sleeping sickness and nagana.
- Its unique redox metabolism involves monothiol glutaredoxin 1 (1CGrx1).
- 1CGrx1 has a unique N-terminal extension and challenging binding sites, hindering drug development.
Purpose of the Study:
- To identify small molecules targeting the 1CGrx1 protein in Trypanosoma brucei.
- To explore novel therapeutic strategies against T. brucei infections.
Main Methods:
- Conducted fragment-based lead discovery and structure-based virtual screening.
- Investigated small molecule binding using Nuclear Magnetic Resonance (NMR).
Main Results:
- Identified a small molecule that binds to the glutathione binding site of 1CGrx1.
- Elucidated the binding mode of the molecule through NMR analysis.
Conclusions:
- The identified compound is a significant step towards developing new strategies against the T. brucei redox system.
- This research opens avenues for novel therapeutic interventions for sleeping sickness.
